No Data
No Data
We Think You Can Look Beyond Sichuan Goldstone Asia Pharmaceutical's (SZSE:300434) Lackluster Earnings
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report Summary
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report
Sichuan Goldstone Pharmaceuticals (300434.SZ) released its performance for the first half of the year, with a net income of 39.2022 million yuan, a decrease of 74.83%.
Sichuan Goldstone (300434.SZ) released its 2024 interim report, and the company's revenue was 0.522 billion...
Sichuan Goldstone (300434.SZ): The net income in the first half of the year was 39.2022 million yuan, a year-on-year decrease of 74.83%.
On August 28th, Goldstone Pharmacy (300434.SZ) released its semi-annual report for the year 2024. During the reporting period, the revenue was 0.522 billion yuan, a decrease of 17.64% year-on-year. The net income attributable to the shareholders of the listed company was 39.2022 million yuan, a decrease of 74.83% year-on-year. The net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 37.0364 million yuan, a decrease of 75.25% year-on-year. The basic earnings per share was 0.0976 yuan.
Sichuan Goldstone Pharmaceuticals (300434.SZ) plans to distribute dividends of 1.1 yuan per 10 shares in 2023, with ex-rights and ex-dividends on June 28.
Sichuan Goldstone Pharmaceutical Co., Ltd. (stock code: 300434.SZ) announced that the company plans to distribute a cash dividend of 1.1 yuan (including tax) per 10 shares to all shareholders in 2023. The equity distribution registration day for this distribution is June 27, 2024, and the ex-rights and ex-dividend date is June 28, 2024.
No Data